Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open label, active-controlled, randomized safety and dose finding study
of different MOD-4023 dose levels compared to daily r-hGH therapy in pre-pubertal growth
hormone deficient children.